CJC-1295 With DAC vs No DAC: Why the Albumin-Binding Moiety Changes the Record
Direct answer
CJC-1295 with DAC and CJC-1295 No DAC should be treated as different research materials because the DAC form includes a reactive albumin-binding modification. A shared GHRH-related name does not make their structures, circulating species, or study records interchangeable.
What DAC identifies
In the original CJC-1295 bioconjugation work, the selected analogue carried a C-terminal maleimide-containing group designed to react with albumin. The study detected an immunoreactive species at the albumin band after administration in rats. That observation supports an albumin-conjugation mechanism for that defined material; it does not identify every product sold under a similar shorthand. Jette et al. (2005)
A comparison table
| Record field | With DAC | No DAC | Why it matters |
|---|---|---|---|
| Structural description | Requires the albumin-binding modification to be stated | Requires its own stated sequence and modifications | The labels describe different materials |
| Circulating species in a study | May include albumin-conjugated material | Cannot be assumed to do so | Sample identity changes the interpretation |
| Assay comparison | Needs matched concentration, matrix, receptor system, and endpoint | Needs the same controls | A potency number alone is incomplete |
| Product documentation | Product identity and lot evidence apply only to that record | Product identity and lot evidence apply only to that record | One record cannot authenticate the other |
How to read a study
First identify the exact analogue named in the methods. Next ask whether the experiment tested free peptide, an albumin-associated species, or a downstream endpoint. Finally, separate pharmacokinetic observations from receptor or cell-assay results. A human study of a specified CJC-1295 preparation is evidence about that study material and protocol, not a performance claim for another material with a related name. Teichman et al. (2006)
Useful links
For the wider GHRH family, compare the separate records for CJC-1295, Sermorelin, and Tesamorelin. The CJC-1295 and Ipamorelin page explains why a blend label adds another identity question. See the Growth Hormone Peptide Terminology foundation before using a category name as a molecular description. The relevant catalog records are CJC-1295 with DAC and CJC-1295 No DAC, within Growth Hormone Peptides.
Limitations
The published albumin-conjugation findings are model- and material-specific. They do not establish purity, lot composition, biological activity, human use, or equivalence for a catalog item. A COA can document stated testing for a specific lot, but it cannot replace a structural description of the material used in a paper.
FAQ
Does “long acting” identify the material? No. It is a description used in particular studies; the structural record still needs the exact analogue and modification.
Can DAC and No DAC results be put in one table? They can be displayed together only when the table keeps the materials, model, matrix, endpoint, and source separate.
Further interpretation
Albumin association is also a reminder that a study may measure a changing population of species rather than one unchanged free peptide. A method section can state when samples were collected, how material was detected, and whether an albumin-associated band was observed. That sequence of evidence is more informative than using a duration descriptor as a substitute for structure. It also explains why a result generated from a defined DAC analogue should retain the modification in its table heading, figure legend, and comparison notes.
Before comparing records
Before comparing records, list the material name exactly as reported, every stated modification, the biological matrix, the assay endpoint, and the time window. If any of those fields is absent, the comparison should say so. This protects against a common category error: treating a family label as if it were a single, fully specified analyte.
Evidence boundary
The evidence boundary is simple: an albumin-associated signal or duration observation belongs to the named analogue and study design. It cannot establish that an unrelated preparation has the same modification, conjugation behavior, purity, or biological profile.